Generics - Financial, Patents

Filter

Current filters:

FinancialPatents

Popular Filters

Low level of “potentially problematic” patent settlements in EU pharma sector

Low level of “potentially problematic” patent settlements in EU pharma sector

09-12-2013

The European Commission's report on patent settlement agreements, also referred to as “pay-for-delay”…

EuropeFinancialGenericsPatentsPharmaceutical

AstraZeneca wins damages from Apotex

AstraZeneca wins damages from Apotex

04-12-2013

Anglo-Swedish drug major AstraZeneca this morning said it welcomed the US District Court for the Southern…

ApotexAstraZenecaFinancialGastro-intestinalsGenericsNexium I.V.North AmericaPatentsPrilosec

Indian citizens lack free access to essential generic medicines, while policies risk undermining new drug research funding

17-07-2013

Modern India has the third largest national economy in the world in purchasing power adjusted terms.…

Asia-PacificFinancialGenericsHealthcarePatentsResearch

US pharma patent settlements netted $25.5 billion in savings for health system; report

10-07-2013

Generic pharmaceuticals launched prior to patent expiration due to a patent settlement - also called…

FinancialGenericsNorth AmericaPatentsPharmaceutical

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Tightening health budgets on both sides of the Atlantic leading to crackdowns on patent settlements, says EIU analyst

05-06-2013

Later this month, following an inquiry launched in 2009, the European Commission is expected to impose…

EuropeFinancialGenericsNorth AmericaPatentsPharmaceuticalPoliticsRegulation

Drugmakers to continue facing growing generic competition in 2013

17-02-2013

Last year saw the expiration of patents for several blockbuster drugs, leading to increasing generic…

AmarinFinancialForest LaboratoriesGenericsPatentsPharmaceutical

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million

12-12-2012

Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Pharma vs the world: Big Pharma caught between investors and public

23-09-2012

Big Pharma today encounters a variety of pressures from generics manufacturers, governments, patient…

FinancialGenericsGlobalMarkets & MarketingPatentsPharmaceuticalPoliticsSanofi

Sanofi fourth-quarter in line with forecasts; collects damages

08-02-2012

French drug major Sanofi (Euronext: SAN) this morning reported 8.8% growth in fourth-quarter 2011 sales…

ApotexBristol-Myers SquibbFinancialGenericsLegalPatentsPharmaceuticalPlavix

Back to top